{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:18:54Z","timestamp":1791195534788,"version":"4.1.0"},"reference-count":496,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.pharmr.2026.100147","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:46:56Z","timestamp":1781308016000},"page":"100147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Recent advances in methotrexate pharmacology and potential therapeutic uses in age-related cardiometabolic and neurodegenerative diseases"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8699-1412","authenticated-orcid":false,"given":"Arduino A.","family":"Mangoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4886-0416","authenticated-orcid":false,"given":"Julie-Ann","family":"Hulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9449-2602","authenticated-orcid":false,"given":"Sara","family":"Tommasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib1","article-title":"Public health challenges and responses to the growing ageing populations","volume":"3","author":"Khan","year":"2024","journal-title":"Public Health Chall"},{"key":"10.1016\/j.pharmr.2026.100147_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101860","article-title":"Global and regional prevalence of multimorbidity in the adult population in community settings: a systematic review and meta-analysis","volume":"57","author":"Chowdhury","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.pharmr.2026.100147_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1423016","article-title":"Accelerated biological aging: unveiling the path to cardiometabolic multimorbidity, dementia, and mortality","volume":"12","author":"He","year":"2024","journal-title":"Front Public Health"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jacasi.2024.02.002","article-title":"Impact of aging on cardiovascular diseases: from chronological observation to biological insights: JACC family series","volume":"4","author":"Zhao","year":"2024","journal-title":"JACC Asia"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib5","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jacc.2019.06.053","article-title":"Cardiovascular aging and heart failure: JACC review topic of the week","volume":"74","author":"Triposkiadis","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40035-024-00397-x","article-title":"The interaction between ageing and Alzheimer's disease: insights from the hallmarks of ageing","volume":"13","author":"Liu","year":"2024","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.pharmr.2026.100147_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40035-019-0165-9","article-title":"The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson's disease","volume":"8","author":"Pang","year":"2019","journal-title":"Transl Neurodegener"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib8","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/svn-2025-004048","article-title":"Updates on vascular dementia","volume":"10","author":"Ng","year":"2025","journal-title":"Stroke Vasc Neurol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s44400-025-00022-2","article-title":"Risk factors and predictors for Lewy body dementia: a systematic review","volume":"1","author":"Ratnavel","year":"2025","journal-title":"NPJ Dement"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094901","article-title":"Age-related incidence and family history in frontotemporal dementia: data from the Swedish Dementia Registry","volume":"9","author":"Nilsson","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib11","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ejim.2013.10.001","article-title":"Chronic obstructive pulmonary disease in the elderly","volume":"25","author":"Incalzi","year":"2014","journal-title":"Eur J Intern Med"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib12","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nrrheum.2016.65","article-title":"Ageing and the pathogenesis of osteoarthritis","volume":"12","author":"Loeser","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.pharmr.2026.100147_bib13","article-title":"The multi-faceted nature of age-associated osteoporosis","volume":"20","author":"Smit","year":"2024","journal-title":"Bone Rep"},{"key":"10.1016\/j.pharmr.2026.100147_bib14","article-title":"Global, regional, and national burden and trends of rheumatoid arthritis among the elderly population: an analysis based on the 2021 Global Burden of Disease study","volume":"16","author":"Wei","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41392-022-01251-0","article-title":"Aging and aging-related diseases: from molecular mechanisms to interventions and treatments","volume":"7","author":"Guo","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12964-024-01663-1","article-title":"Molecular mechanisms of aging and anti-aging strategies","volume":"22","author":"Li","year":"2024","journal-title":"Cell Commun Signal"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib17","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","article-title":"The hallmarks of aging","volume":"153","author":"Lopez-Otin","year":"2013","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cell.2022.11.001","article-title":"Hallmarks of aging: An expanding universe","volume":"186","author":"Lopez-Otin","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41392-023-01502-8","article-title":"Inflammation and aging: signaling pathways and intervention therapies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.pharmr.2026.100147_bib20","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1749-6632.2000.tb06651.x","article-title":"Inflamm-aging: an evolutionary perspective on immunosenescence","volume":"908","author":"Franceschi","year":"2000","journal-title":"Ann N Y Acad Sci"},{"issue":"26","key":"10.1016\/j.pharmr.2026.100147_bib21","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.2174\/138161209789058110","article-title":"An update of the oxidation-inflammation theory of aging: The involvement of the immune system in oxi-inflamm-aging","volume":"15","author":"De la Fuente","year":"2009","journal-title":"Curr Pharm Des"},{"issue":"7437","key":"10.1016\/j.pharmr.2026.100147_bib22","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nature11824","article-title":"T-helper-1-cell cytokines drive cancer into senescence","volume":"494","author":"Braumuller","year":"2013","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.pharmr.2026.100147_bib23","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.3390\/ijms20184472","article-title":"Inflammaging and oxidative stress in human diseases: from molecular mechanisms to novel treatments","volume":"20","author":"Zuo","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.arr.2007.09.002","article-title":"Activation of innate immunity system during aging: NF-kB signaling is the molecular culprit of inflamm-aging","volume":"7","author":"Salminen","year":"2008","journal-title":"Ageing Res Rev"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib25","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.arr.2011.12.005","article-title":"AMP-activated protein kinase (AMPK) controls the aging process via an integrated signaling network","volume":"11","author":"Salminen","year":"2012","journal-title":"Ageing Res Rev"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib26","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.pharmr.2026.100147_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102550","article-title":"HMGB1, an evolving pleiotropic protein critical for cellular and tissue homeostasis: role in aging and age-related diseases","volume":"102","author":"Ruggieri","year":"2024","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.pharmr.2026.100147_bib28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.smim.2018.09.001","article-title":"NLRP3 inflammasome activation in inflammaging","volume":"40","author":"Latz","year":"2018","journal-title":"Semin Immunol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100147_bib29","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.3390\/ijms20112774","article-title":"mTOR and aging: an old fashioned dress","volume":"20","author":"Stallone","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"20","key":"10.1016\/j.pharmr.2026.100147_bib30","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.3390\/ijms20205002","article-title":"TGF-\u03b2 signaling in cellular senescence and aging-related pathology","volume":"20","author":"Tominaga","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharmr.2026.100147_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1704203","article-title":"Inflammaging: triggers, molecular mechanisms, immunological consequences, sex differences, and cutaneous manifestations","volume":"16","author":"Karpuzoglu","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.pharmr.2026.100147_bib32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.arr.2016.06.004","article-title":"The emerging role of Notch pathway in ageing: focus on the related mechanisms in age-related diseases","volume":"29","author":"Balistreri","year":"2016","journal-title":"Ageing Res Rev"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib33","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-022-01257-8","article-title":"The sirtuin family in health and disease","volume":"7","author":"Wu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"22","key":"10.1016\/j.pharmr.2026.100147_bib34","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3390\/cells13221906","article-title":"Inflammation: the cause of all diseases","volume":"13","author":"Chavda","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41577-024-01075-9","article-title":"Inflammasome components as new therapeutic targets in inflammatory disease","volume":"25","author":"Coll","year":"2025","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100147_bib36","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1161\/ATVBAHA.124.319980","article-title":"Novel therapeutics and upcoming clinical trials targeting inflammation in cardiovascular diseases","volume":"44","author":"Potere","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib37","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer's disease: mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.pharmr.2026.100147_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1196413","article-title":"Alzheimer's disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy?","volume":"14","author":"Melchiorri","year":"2023","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100147_bib39","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-021-00198-1","article-title":"Targeting inflammation in atherosclerosis: from experimental insights to the clinic","volume":"20","author":"Soehnlein","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100147_bib40","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1021\/acsptsci.9b00097","article-title":"Therapeutic potential of lipoxin A4 in chronic inflammation: focus on cardiometabolic disease","volume":"3","author":"Fu","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib42","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1161\/CIRCRESAHA.124.324383","article-title":"Emerging roles and therapeutic applications of arachidonic acid pathways in cardiometabolic diseases","volume":"135","author":"Hu","year":"2024","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib43","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41392-024-01811-6","article-title":"Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets","volume":"9","author":"Fleishman","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10753-022-01721-1","article-title":"Neuroinflammation in Alzheimer's disease: current progress in molecular signaling and therapeutics","volume":"46","author":"Thakur","year":"2023","journal-title":"Inflammation"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100147_bib45","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1038\/s41380-023-02239-0","article-title":"Targeting NLRP3 inflammasome for neurodegenerative disorders","volume":"28","author":"Yao","year":"2023","journal-title":"Mol Psychiatry"},{"issue":"15","key":"10.1016\/j.pharmr.2026.100147_bib46","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s40265-023-01938-w","article-title":"Alzheimer's disease: novel targets and investigational drugs for disease modification","volume":"83","author":"Cummings","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.pharmr.2026.100147_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2025.103787","article-title":"Decoding Parkinson's disease: the interplay of cell death pathways, oxidative stress, and therapeutic innovations","volume":"85","author":"Liu","year":"2025","journal-title":"Redox Biol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib48","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.3390\/cells9071687","article-title":"Inflammation in Parkinson's disease: mechanisms and therapeutic implications","volume":"9","author":"Pajares","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100147_bib50","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib51","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/cts.12538","article-title":"It's time to reverse our thinking: the reverse translation research paradigm","volume":"11","author":"Shakhnovich","year":"2018","journal-title":"Clin Transl Sci"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib52","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41435-023-00217-8","article-title":"Reverse translation: the key to increasing the clinical success of immunotherapy?","volume":"24","author":"Vanmeerbeek","year":"2023","journal-title":"Genes Immun"},{"key":"10.1016\/j.pharmr.2026.100147_bib53","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejim.2021.10.002","article-title":"Colchicine - new horizons for an ancient drug. Review based on the highest hierarchy of evidence","volume":"96","author":"Schattner","year":"2022","journal-title":"Eur J Intern Med"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib54","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1161\/ATVBAHA.124.319851","article-title":"Colchicine's role in cardiovascular disease management","volume":"44","author":"Buckley","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmr.2026.100147_bib55","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1146\/annurev-pharmtox-052120-020445","article-title":"Repurposing colchicine for heart disease","volume":"62","author":"Bouabdallaoui","year":"2022","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"23","key":"10.1016\/j.pharmr.2026.100147_bib56","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid","volume":"238","author":"Farber","year":"1948","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib57","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/jama.1965.03090140083021","article-title":"New treatment schedule with improved survival in childhood leukemia. Intermittent parenteral vs daily oral administration of methotrexate for maintenance of induced remission. Acute leukemia group B","volume":"194","author":"Selawry","year":"1965","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib58","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/1097-0142(197609)38:3<1043::AID-CNCR2820380302>3.0.CO;2-U","article-title":"Methotrexate and citrovorum factor rescue in the management of childhood lymphosarcoma and reticulum cell sarcoma (non-Hodgkin's lymphomas): parolonged unmaintained remissions","volume":"38","author":"Djerassi","year":"1976","journal-title":"Cancer"},{"key":"10.1016\/j.pharmr.2026.100147_bib59","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.1964.03070100037007","article-title":"Methotrexate therapy in psoriatic arthritis: double-blind study on 21 patients","volume":"189","author":"Black","year":"1964","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib60","first-page":"501","article-title":"Low dose pulse methotrexate therapy in rheumatoid arthritis","volume":"7","author":"Willkens","year":"1980","journal-title":"J Rheumatol"},{"issue":"6A","key":"10.1016\/j.pharmr.2026.100147_bib61","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9343(83)90477-1","article-title":"Methotrexate therapy in rheumatoid arthritis: 15 years experience","volume":"75","author":"Hoffmeister","year":"1983","journal-title":"Am J Med"},{"key":"10.1016\/j.pharmr.2026.100147_bib62","first-page":"16","article-title":"Methotrexate in rheumatoid arthritis: a quarter century of development","volume":"124","author":"Weinblatt","year":"2013","journal-title":"Trans Am Clin Climatol Assoc"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib63","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/0961203313519159","article-title":"Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy","volume":"23","author":"Sakthiswary","year":"2014","journal-title":"Lupus"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib64","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3899\/jrheum.101262","article-title":"Expert agreement on EULAR\/EUSTAR recommendations for the management of systemic sclerosis","volume":"38","author":"Walker","year":"2011","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib65","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa2501443","article-title":"First-line treatment of pulmonary sarcoidosis with prednisone or methotrexate","volume":"393","author":"Kahlmann","year":"2025","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100147_bib66","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.pharmr.2026.100147_bib67","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.3390\/ijms20205023","article-title":"Methotrexate: an old drug with new tricks","volume":"20","author":"Bedoui","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100147_bib68","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1111\/bcp.14057","article-title":"Optimising low-dose methotrexate for rheumatoid arthritis: a review","volume":"85","author":"Lucas","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100147_bib69","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3390\/ph5080802","article-title":"Involvement of multiple transporters-mediated transports in mizoribine and methotrexate pharmacokinetics","volume":"5","author":"Murakami","year":"2012","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib70","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.bbrc.2013.01.004","article-title":"Transcriptional regulation of PCFT by KLF4, HNF4\u03b1, CDX2 and C\/EBP\u03b1: implication in its site-specific expression in the small intestine","volume":"431","author":"Furumiya","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmr.2026.100147_bib71","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/B978-0-12-800223-0.00004-9","article-title":"Biology of the major facilitative folate transporters SLC19A1 and SLC46A1","volume":"73","author":"Hou","year":"2014","journal-title":"Curr Top Membr"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib72","first-page":"645","article-title":"Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis","volume":"31","author":"Hoekstra","year":"2004","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib73","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/mr\/roac156","article-title":"Subcutaneous injection of methotrexate: advantages in the treatment of rheumatoid arthritis","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib74","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2133\/dmpk.DMPK-13-RV-119","article-title":"Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy","volume":"29","author":"Inoue","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib75","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0006-291X(73)90949-2","article-title":"Polygammaglutamyl metabolites of methotrexate","volume":"52","author":"Baugh","year":"1973","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100147_bib76","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/17512433.2024.2416674","article-title":"Methotrexate polyglutamates","volume":"17","author":"Yang","year":"2024","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100147_bib77","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2016.175","article-title":"Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers","volume":"12","author":"Brown","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100147_bib78","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1096\/fasebj.4.8.2185970","article-title":"Dihydrofolate reductase as a therapeutic target","volume":"4","author":"Schweitzer","year":"1990","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmr.2026.100147_bib79","series-title":"Antifolate Drugs in Cancer Therapy","first-page":"183","article-title":"Preclinical pharmacology studies and the clinical development of a novel multitargeted antifolate, MTA (LY231514)","author":"Shih","year":"1999"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib80","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/RHU.0000000000000810","article-title":"Folate supplementation for methotrexate therapy in patients with rheumatoid arthritis: a systematic review","volume":"25","author":"Liu","year":"2019","journal-title":"J Clin Rheumatol"},{"issue":"Pt 1","key":"10.1016\/j.pharmr.2026.100147_bib81","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/bj3420143","article-title":"Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis?","volume":"342","author":"Fairbanks","year":"1999","journal-title":"Biochem J"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib82","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1042\/bj2360193","article-title":"Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide","volume":"236","author":"Baggott","year":"1986","journal-title":"Biochem J"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib83","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1073\/pnas.88.6.2441","article-title":"Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells","volume":"88","author":"Cronstein","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib84","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1172\/JCI116884","article-title":"The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation","volume":"92","author":"Cronstein","year":"1993","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib85","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/art.10712","article-title":"Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68","volume":"48","author":"Montesinos","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib86","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1152\/physrev.00049.2017","article-title":"Pharmacology of adenosine receptors: the state of the art","volume":"98","author":"Borea","year":"2018","journal-title":"Physiol Rev"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib87","doi-asserted-by":"crossref","DOI":"10.1186\/ar3527","article-title":"A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release","volume":"13","author":"Varani","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib88","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1189\/jlb.2VMA1216-517R","article-title":"Early tyrosine phosphorylation events following adenosine A(2A) receptor in human neutrophils: identification of regulated pathways","volume":"102","author":"Giambelluca","year":"2017","journal-title":"J Leukoc Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib89","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrrheum.2016.178","article-title":"Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases","volume":"13","author":"Cronstein","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib90","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1165\/rcmb.2008-0168OC","article-title":"The adenosine A2A receptor inhibits matrix-induced inflammation in a novel fashion","volume":"40","author":"Scheibner","year":"2009","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib91","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1091\/mbc.e06-07-0596","article-title":"Synergistic up-regulation of vascular endothelial growth factor (VEGF) expression in macrophages by adenosine A2A receptor agonists and endotoxin involves transcriptional regulation via the hypoxia response element in the VEGF promoter","volume":"18","author":"Ramanathan","year":"2007","journal-title":"Mol Biol Cell"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100147_bib92","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/jcp.24568","article-title":"Adenosine regulates the proinflammatory signaling function of thrombin in endothelial cells","volume":"229","author":"Hassanian","year":"2014","journal-title":"J Cell Physiol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib93","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood.V90.4.1600","article-title":"Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion","volume":"90","author":"Huang","year":"1997","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib94","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1189\/jlb.0204107","article-title":"Adenosine A2A receptor occupancy stimulates expression of proteins involved in reverse cholesterol transport and inhibits foam cell formation in macrophages","volume":"76","author":"Reiss","year":"2004","journal-title":"J Leukoc Biol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib95","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.bbalip.2012.11.005","article-title":"Adenosine A(2A) receptor activation supports an atheroprotective cholesterol balance in human macrophages and endothelial cells","volume":"1831","author":"Voloshyna","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100147_bib96","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1002\/art.24040","article-title":"Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte\/macrophages","volume":"58","author":"Reiss","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib97","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/CIRCRESAHA.113.302089","article-title":"Systemic delivery of microRNA-181b inhibits nuclear factor-kappaB activation, vascular inflammation, and atherosclerosis in apolipoprotein E-deficient mice","volume":"114","author":"Sun","year":"2014","journal-title":"Circ Res"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100147_bib98","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1096\/fj.201500163R","article-title":"MicroRNA-181b inhibits thrombin-mediated endothelial activation and arterial thrombosis by targeting caspase recruitment domain family member 10","volume":"30","author":"Lin","year":"2016","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmr.2026.100147_bib99","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.58064","article-title":"Methotrexate attenuates vascular inflammation through an adenosine-microRNA-dependent pathway","volume":"10","author":"Yang","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.pharmr.2026.100147_bib100","article-title":"Effects of Methotrexate in a Rabbit Model of In-Stent Neoatherosclerosis: An Optical Coherence Tomography Study","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib101","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1006\/jmcc.2000.1298","article-title":"Functional and molecular characterization of receptor subtypes mediating coronary microvascular dilation to adenosine","volume":"33","author":"Hein","year":"2001","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib102","doi-asserted-by":"crossref","first-page":"F457","DOI":"10.1152\/ajprenal.00567.2010","article-title":"Adenosine A2A receptor activation attenuates tubuloglomerular feedback responses by stimulation of endothelial nitric oxide synthase","volume":"300","author":"Carlstrom","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib103","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040584","article-title":"The A2b adenosine receptor modulates glucose homeostasis and obesity","volume":"7","author":"Johnston-Cox","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib104","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2337\/db14-0508","article-title":"Methotrexate promotes glucose uptake and lipid oxidation in skeletal muscle via AMPK activation","volume":"64","author":"Pirkmajer","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2026.100147_bib105","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/132056","article-title":"Methotrexate Increases Skeletal Muscle GLUT4 Expression and Improves Metabolic Control in Experimental Diabetes","volume":"2012","author":"Russo","year":"2012","journal-title":"J Nutr Metab"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib106","doi-asserted-by":"crossref","first-page":"E1358","DOI":"10.1152\/ajpendo.00573.2006","article-title":"A1 adenosine receptor partial agonist lowers plasma FFA and improves insulin resistance induced by high-fat diet in rodents","volume":"292","author":"Dhalla","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib107","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1139\/H07-039","article-title":"Activation of the A1 adenosine receptor increases insulin-stimulated glucose transport in isolated rat soleus muscle","volume":"32","author":"Thong","year":"2007","journal-title":"Appl Physiol Nutr Metab"},{"key":"10.1016\/j.pharmr.2026.100147_bib108","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejphar.2017.02.017","article-title":"Role of A(1) and A(2A) adenosine receptor agonists in adipose tissue inflammation induced by obesity in mice","volume":"799","author":"DeOliveira","year":"2017","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib109","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1179\/016164105X18278","article-title":"Effects of adenosine and adenosine A2A receptor agonist on motor nerve conduction velocity and nerve blood flow in experimental diabetic neuropathy","volume":"27","author":"Kumar","year":"2005","journal-title":"Neurol Res"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib110","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.ajpath.2011.01.018","article-title":"A((2)A) adenosine receptor (A((2)A)AR) as a therapeutic target in diabetic retinopathy","volume":"178","author":"Ibrahim","year":"2011","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib111","doi-asserted-by":"crossref","first-page":"F828","DOI":"10.1152\/ajprenal.00310.2005","article-title":"Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy","volume":"290","author":"Awad","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib112","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.29777","article-title":"Disruption of adenosine 2A receptor exacerbates NAFLD through increasing inflammatory responses and SREBP1c activity","volume":"68","author":"Cai","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib113","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cmet.2020.06.006","article-title":"Adenosine\/A2B Receptor Signaling Ameliorates the Effects of Aging and Counteracts Obesity","volume":"32","author":"Gnad","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2026.100147_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2024.115210","article-title":"Effect of simultaneous application of adenosine A1 receptor agonist and A2A receptor antagonist on memory, inflammatory factors, and PSD-95 in lipopolysaccharide-induced memory impairment","volume":"476","author":"Ensandoust","year":"2025","journal-title":"Behav Brain Res"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib115","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/(SICI)1098-2396(199712)27:4<322::AID-SYN6>3.0.CO;2-E","article-title":"Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study","volume":"27","author":"Svenningsson","year":"1997","journal-title":"Synapse"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib116","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.expneurol.2010.07.011","article-title":"Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders","volume":"225","author":"Hodgson","year":"2010","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmr.2026.100147_bib117","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ibneur.2024.07.005","article-title":"Efficacy of preladenant in improving motor symptoms in Parkinson's disease: A systematic review and meta-analysis","volume":"17","author":"Karimi","year":"2024","journal-title":"IBRO Neurosci Rep"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib118","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/cells14050338","article-title":"A(2A) Adenosine Receptor Antagonists and Their Efficacy in Rat Models of Parkinson's Disease","volume":"14","author":"Spinaci","year":"2025","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100147_bib119","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.3390\/ijms26125680","article-title":"The Anti-Parkinsonian A2A Receptor Antagonist Istradefylline (KW-6002) Attenuates Behavioral Abnormalities, Neuroinflammation, and Neurodegeneration in Cerebral Ischemia: An Adenosinergic Signaling Link Between Stroke and Parkinson's Disease","volume":"26","author":"Zaki","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib120","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1161\/STROKEAHA.121.035499","article-title":"Depression, Anxiety, and Suicide After Stroke: A Narrative Review of the Best Available Evidence","volume":"53","author":"Chun","year":"2022","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib121","doi-asserted-by":"crossref","DOI":"10.1186\/ar1914","article-title":"Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis","volume":"8","author":"Montesinos","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.pharmr.2026.100147_bib122","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"issue":"5 Suppl 101","key":"10.1016\/j.pharmr.2026.100147_bib123","first-page":"S40","article-title":"The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis","volume":"34","author":"van Riel","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib124","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41397-019-0098-9","article-title":"Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review","volume":"20","author":"Eektimmerman","year":"2020","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.pharmr.2026.100147_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152337","article-title":"A meta-analysis of the association between the ATIC 347 C\/G polymorphism and methotrexate responsiveness and toxicity in rheumatoid arthritis","volume":"64","author":"Lee","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100147_bib126","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nri3520","article-title":"Macrophages in atherosclerosis: a dynamic balance","volume":"13","author":"Moore","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"18","key":"10.1016\/j.pharmr.2026.100147_bib127","doi-asserted-by":"crossref","first-page":"8592","DOI":"10.1073\/pnas.91.18.8592","article-title":"Atherosclerosis and sterol 27-hydroxylase: evidence for a role of this enzyme in elimination of cholesterol from human macrophages","volume":"91","author":"Bjorkhem","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib128","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.bbalip.2006.04.012","article-title":"Lipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1","volume":"1761","author":"Cavelier","year":"2006","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib129","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.clinthera.2012.03.059","article-title":"A randomized, double-blind, parallel, single-site pilot trial to compare two different starting doses of methotrexate in methotrexate-naive adult patients with rheumatoid arthritis","volume":"34","author":"Hobl","year":"2012","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib130","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3390\/molecules22040676","article-title":"Adenosine A1 and A2A Receptors in the Brain: Current Research and Their Role in Neurodegeneration","volume":"22","author":"Stockwell","year":"2017","journal-title":"Molecules"},{"issue":"16-18","key":"10.1016\/j.pharmr.2026.100147_bib131","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1089\/ars.2023.0455","article-title":"Adenosine A2A Receptor Antagonist Sch58261 Improves the Cognitive Function in Alzheimer's Disease Model Mice Through Activation of Nrf2 via an Autophagy-Dependent Pathway","volume":"41","author":"Sun","year":"2024","journal-title":"Antioxid Redox Signal"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib132","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1007\/s11357-025-01526-8","article-title":"Blockade of A(2A)R improved brain perfusion and cognitive function in a mouse model of Alzheimer's disease","volume":"47","author":"Udo","year":"2025","journal-title":"Geroscience"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib133","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1432-1033.1995.tb20498.x","article-title":"5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?","volume":"229","author":"Corton","year":"1995","journal-title":"Eur J Biochem"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib134","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrm3311","article-title":"AMPK: a nutrient and energy sensor that maintains energy homeostasis","volume":"13","author":"Hardie","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib135","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051095","article-title":"AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review","volume":"10","author":"Visnjic","year":"2021","journal-title":"Cells"},{"issue":"Pt 5","key":"10.1016\/j.pharmr.2026.100147_bib136","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1107\/S0907444907009110","article-title":"Structure of a CBS-domain pair from the regulatory gamma1 subunit of human AMPK in complex with AMP and ZMP","volume":"63","author":"Day","year":"2007","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib137","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3109\/10409238.2010.488215","article-title":"AMPK inhibition in health and disease","volume":"45","author":"Viollet","year":"2010","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib138","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1074\/jbc.M306205200","article-title":"Knockout of the alpha2 but not alpha1 5'-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle","volume":"279","author":"Jorgensen","year":"2004","journal-title":"J Biol Chem"},{"issue":"Pt 2","key":"10.1016\/j.pharmr.2026.100147_bib139","article-title":"Targeting of AMPK\/MTOR signaling in the management of atherosclerosis: Outmost leveraging","volume":"309","author":"Al-Kuraishy","year":"2025","journal-title":"Int J Biol Macromol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib140","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41580-022-00547-x","article-title":"New insights into activation and function of the AMPK","volume":"24","author":"Steinberg","year":"2023","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100147_bib141","doi-asserted-by":"crossref","first-page":"15390","DOI":"10.1007\/s12035-025-05162-3","article-title":"Multiple Mechanisms and Therapeutic Strategies for the Involvement of AMPK in the Development of Alzheimer's Disease","volume":"62","author":"Yu","year":"2025","journal-title":"Mol Neurobiol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib142","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3233\/JPD-171296","article-title":"Targeting AMPK Signaling as a Neuroprotective Strategy in Parkinson's Disease","volume":"8","author":"Curry","year":"2018","journal-title":"J Parkinsons Dis"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100147_bib143","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1016\/j.apsb.2021.02.016","article-title":"Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease","volume":"11","author":"Zhang","year":"2021","journal-title":"Acta Pharm Sin B"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib144","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1136\/annrheumdis-2014-206305","article-title":"Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation","volume":"75","author":"Thornton","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib145","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12933-018-0777-x","article-title":"Perivascular adipose tissue (PVAT) in atherosclerosis: a double-edged sword","volume":"17","author":"Qi","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib146","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.3892\/mmr.2017.6225","article-title":"Methotrexate improves perivascular adipose tissue\/endothelial dysfunction via activation of AMPK\/eNOS pathway","volume":"15","author":"Ma","year":"2017","journal-title":"Mol Med Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib147","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1186\/s12967-019-02135-8","article-title":"Atheroprotective effects of methotrexate via the inhibition of YAP\/TAZ under disturbed flow","volume":"17","author":"Liu","year":"2019","journal-title":"J Transl Med"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100147_bib148","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/j.1460-2075.1990.tb07420.x","article-title":"Regulation of HMG-CoA reductase: identification of the site phosphorylated by the AMP-activated protein kinase in vitro and in intact rat liver","volume":"9","author":"Clarke","year":"1990","journal-title":"EMBO J"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib149","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1161\/ATVBAHA.118.311212","article-title":"Metformin and AMP Kinase Activation Increase Expression of the Sterol Transporters ABCG5\/8 (ATP-Binding Cassette Transporter G5\/G8) With Potential Antiatherogenic Consequences","volume":"38","author":"Molusky","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib150","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.bbrc.2005.12.011","article-title":"AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARalpha and PGC-1","volume":"340","author":"Lee","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"1-2","key":"10.1016\/j.pharmr.2026.100147_bib151","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.mce.2012.03.016","article-title":"Effects of methotrexate on inflammatory alterations induced by obesity: an in vivo and in vitro study","volume":"361","author":"DeOliveira","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib152","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102420","article-title":"The anti-diabetic drug metformin reduces BACE1 protein level by interfering with the MID1 complex","volume":"9","author":"Hettich","year":"2014","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.pharmr.2026.100147_bib153","doi-asserted-by":"crossref","first-page":"15673","DOI":"10.1021\/acsomega.5c00535","article-title":"Trelagliptin ameliorates memory decline in diabetic rats through the AMPK\/AKT\/GSK-3\u03b2 pathway in the cerebral cortex","volume":"10","author":"Yao","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.pharmr.2026.100147_bib154","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cotox.2018.05.002","article-title":"mTOR\/AMPK signaling in the brain: cell metabolism, proteostasis and survival","volume":"8","author":"Garza-Lombo","year":"2018","journal-title":"Curr Opin Toxicol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100147_bib155","doi-asserted-by":"crossref","first-page":"7767","DOI":"10.1007\/s12035-024-04048-0","article-title":"The protective effects of syringic acid on bisphenol A-induced neurotoxicity possibly through AMPK\/PGC-1\u03b1\/Fndc5 and CREB\/BDNF signaling pathways","volume":"61","author":"Helli","year":"2024","journal-title":"Mol Neurobiol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100147_bib156","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1007\/s12035-020-01955-w","article-title":"Upregulation of AMPK ameliorates Alzheimer's disease-like tau pathology and memory impairment","volume":"57","author":"Wang","year":"2020","journal-title":"Mol Neurobiol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib157","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ncb2152","article-title":"AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1","volume":"13","author":"Kim","year":"2011","journal-title":"Nat Cell Biol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib158","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1080\/08923973.2022.2096464","article-title":"The AMPK-SIRT1-FoxO1-NF-kappaB signaling pathway participates in hesperetin-mediated neuroprotective effects against traumatic brain injury via the NLRP3 inflammasome","volume":"44","author":"Song","year":"2022","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib159","doi-asserted-by":"crossref","first-page":"E751","DOI":"10.1152\/ajpendo.00745.2009","article-title":"AMPK and SIRT1: a long-standing partnership?","volume":"298","author":"Ruderman","year":"2010","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib160","doi-asserted-by":"crossref","first-page":"110","DOI":"10.31083\/j.jin2205110","article-title":"Metformin ameliorates postoperative cognitive dysfunction through regulation of the AMPK\/SIRT1 pathway","volume":"22","author":"Jia","year":"2023","journal-title":"J Integr Neurosci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib161","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20170862","article-title":"Insulin degrading enzyme contributes to the pathology in a mixed model of type 2 diabetes and Alzheimer's disease: possible mechanisms of IDE in T2D and AD","volume":"38","author":"Li","year":"2018","journal-title":"Biosci Rep"},{"key":"10.1016\/j.pharmr.2026.100147_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114473","article-title":"Magnolol improves Alzheimer's disease-like pathologies and cognitive decline by promoting autophagy through activation of the AMPK\/mTOR\/ULK1 pathway","volume":"161","author":"Wang","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib163","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s11357-012-9489-4","article-title":"Dietary resveratrol prevents Alzheimer's markers and increases life span in SAMP8","volume":"35","author":"Porquet","year":"2013","journal-title":"Age"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib164","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/s43587-025-00869-3","article-title":"Activation of AMPK by GLP-1R agonists mitigates Alzheimer-related phenotypes in transgenic mice","volume":"5","author":"Zhang","year":"2025","journal-title":"Nat Aging"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib165","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.bbrc.2009.11.022","article-title":"AMP-activated protein kinase is activated in Parkinson's disease models mediated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"391","author":"Choi","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100147_bib166","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyw047","article-title":"Metformin prevents dopaminergic neuron death in MPTP\/P-induced mouse model of Parkinson's disease via autophagy and mitochondrial ROS clearance","volume":"19","author":"Lu","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib167","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.atherosclerosis.2012.09.033","article-title":"5-Aminoimidazole-4-carboxamide ribonucleoside stabilizes low density lipoprotein receptor mRNA in hepatocytes via ERK-dependent HuR binding to an AU-rich element","volume":"226","author":"Yashiro","year":"2013","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib168","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/cvr\/cvt073","article-title":"AICAR inhibits PPARgamma during monocyte differentiation to attenuate inflammatory responses to atherogenic lipids","volume":"98","author":"Namgaladze","year":"2013","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmr.2026.100147_bib169","doi-asserted-by":"crossref","DOI":"10.1038\/srep32111","article-title":"AMPK-independent inhibition of human macrophage ER stress response by AICAR","volume":"6","author":"Boss","year":"2016","journal-title":"Sci Rep"},{"issue":"15","key":"10.1016\/j.pharmr.2026.100147_bib170","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2022113410","article-title":"Regulation of LRRK2 mRNA stability by ATIC and its substrate AICAR through ARE-mediated mRNA decay in Parkinson's disease","volume":"42","author":"Liu","year":"2023","journal-title":"EMBO J"},{"issue":"21","key":"10.1016\/j.pharmr.2026.100147_bib171","doi-asserted-by":"crossref","first-page":"8555","DOI":"10.1073\/pnas.87.21.8555","article-title":"ISGF3, the transcriptional activator induced by interferon alpha, consists of multiple interacting polypeptide chains","volume":"87","author":"Fu","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib172","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaad.2021.06.869","article-title":"Tyrosine kinase 2 and Janus kinase\u2013signal transducer and activator of transcription signaling and inhibition in plaque psoriasis","volume":"86","author":"Krueger","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib173","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12964-017-0177-y","article-title":"The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells","volume":"15","author":"Seif","year":"2017","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.pharmr.2026.100147_bib174","doi-asserted-by":"crossref","DOI":"10.1177\/10742484241248046","article-title":"The role of JAK\/STAT signaling pathway and its downstream influencing factors in the treatment of atherosclerosis","volume":"29","author":"Zhang","year":"2024","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100147_bib175","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1111\/febs.13709","article-title":"The JAK\/STAT pathway in obesity and diabetes","volume":"283","author":"Gurzov","year":"2016","journal-title":"FEBS J"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib176","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.tem.2017.11.001","article-title":"JAK\/STAT: emerging players in metabolism","volume":"29","author":"Dodington","year":"2018","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib177","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3390\/ijms24010864","article-title":"The role of the JAK\/STAT signaling pathway in the pathogenesis of Alzheimer's disease: new potential treatment target","volume":"24","author":"Rusek","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharmr.2026.100147_bib178","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.clim.2016.09.014","article-title":"Role of the JAK\/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases","volume":"189","author":"Yan","year":"2018","journal-title":"Clin Immunol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib179","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130078","article-title":"Methotrexate is a JAK\/STAT pathway inhibitor","volume":"10","author":"Thomas","year":"2015","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100147_bib180","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.3324\/haematol.2017.165738","article-title":"Low-dose methotrexate in myeloproliferative neoplasm models","volume":"102","author":"Chinnaiya","year":"2017","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100147_bib181","doi-asserted-by":"crossref","first-page":"E329","DOI":"10.1002\/ajh.24406","article-title":"Low-dose methotrexate as treatment of myeloproliferative neoplasms: proof of principle of clinical activity","volume":"91","author":"Palandri","year":"2016","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib182","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1111\/bjh.16193","article-title":"Low-dose methotrexate: potential clinical impact on haematological and constitutional symptoms in myeloproliferative neoplasms","volume":"187","author":"Francis","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib183","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13075-017-1378-x","article-title":"Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy","volume":"19","author":"Teitsma","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.pharmr.2026.100147_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.172940","article-title":"JAK-STAT-dependent regulation of scavenger receptors in LPS-activated murine macrophages","volume":"871","author":"Hashimoto","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"18","key":"10.1016\/j.pharmr.2026.100147_bib185","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/bph.13932","article-title":"Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis","volume":"174","author":"Perez-Baos","year":"2017","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib186","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.tibs.2007.02.001","article-title":"ABCA1: at the nexus of cholesterol, HDL and atherosclerosis","volume":"32","author":"Attie","year":"2007","journal-title":"Trends Biochem Sci"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib187","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.bbrc.2015.03.017","article-title":"Endothelin-1 exacerbates development of hypertension and atherosclerosis in modest insulin resistant syndrome","volume":"460","author":"Lin","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib188","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00441-010-0936-1","article-title":"Inhibition of JAK\/STAT signaling pathway prevents high-glucose-induced increase in endothelin-1 synthesis in human endothelial cells","volume":"340","author":"Manea","year":"2010","journal-title":"Cell Tissue Res"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib189","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10557-020-06943-9","article-title":"Inhibition of JAK2 suppresses myelopoiesis and atherosclerosis in Apoe(-\/-) mice","volume":"34","author":"Tang","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib190","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12872-020-01391-7","article-title":"Inhibition of JAK2\/STAT3\/SOCS3 signaling attenuates atherosclerosis in rabbit","volume":"20","author":"Yang","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.pharmr.2026.100147_bib191","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117045","article-title":"Inhibition of JAK-STAT and NF-kappaB signalling systems could be a novel therapeutic target against insulin resistance and type 2 diabetes","volume":"239","author":"Bako","year":"2019","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib192","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13075-023-03249-7","article-title":"The effects of suppressing inflammation by tofacitinib may simultaneously improve glycaemic parameters and inflammatory markers in rheumatoid arthritis patients with comorbid type 2 diabetes: A proof-of-concept, open, prospective, clinical study","volume":"26","author":"Di Muzio","year":"2024","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib193","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/medicina60030360","article-title":"Tofacitinib and baricitinib in type 2 diabetic patients with rheumatoid arthritis","volume":"60","author":"Martinez-Molina","year":"2024","journal-title":"Medicina"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib194","doi-asserted-by":"crossref","first-page":"454","DOI":"10.4239\/wjd.v13.i6.454","article-title":"Immediate-release tofacitinib reduces insulin resistance in non-diabetic active rheumatoid arthritis patients: a single-center retrospective study","volume":"13","author":"Wang","year":"2022","journal-title":"World J Diabetes"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100147_bib195","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/ndt\/gfx377","article-title":"JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a phase 2 randomized controlled clinical trial","volume":"33","author":"Tuttle","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmr.2026.100147_bib196","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jneuroim.2017.11.015","article-title":"Resveratrol protects hippocampal neurons against cerebral ischemia-reperfusion injury via modulating JAK\/ERK\/STAT signaling pathway in rats","volume":"315","author":"Chang","year":"2018","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib197","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12974-019-1565-6","article-title":"Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro","volume":"16","author":"Gavegnano","year":"2019","journal-title":"J Neuroinflammation"},{"issue":"18","key":"10.1016\/j.pharmr.2026.100147_bib198","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1523\/JNEUROSCI.4658-15.2016","article-title":"Inhibition of the JAK\/STAT pathway protects against \u03b1-synuclein-induced neuroinflammation and dopaminergic neurodegeneration","volume":"36","author":"Qin","year":"2016","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib199","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12974-024-03210-8","article-title":"Suppression of the JAK\/STAT pathway inhibits neuroinflammation in the line 61-PFF mouse model of Parkinson's disease","volume":"21","author":"Hong","year":"2024","journal-title":"J Neuroinflammation"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib200","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib201","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamadermatol.2023.4090","article-title":"Cardiovascular and venous thromboembolic risk with JAK inhibitors in immune-mediated inflammatory skin diseases: a systematic review and meta-analysis","volume":"160","author":"Ingrassia","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.pharmr.2026.100147_bib202","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1237234","article-title":"Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis","volume":"14","author":"Wei","year":"2023","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib203","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1432-1033.1973.tb03188.x","article-title":"Isolation and characterisation of two calf-thymus chromatin non-histone proteins with high contents of acidic and basic amino acids","volume":"40","author":"Goodwin","year":"1973","journal-title":"Eur J Biochem"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100147_bib204","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41577-023-00894-6","article-title":"The multifunctional protein HMGB1: 50 years of discovery","volume":"23","author":"Tang","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pharmr.2026.100147_bib205","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2025.156259","article-title":"Propagation of senescent phenotypes by extracellular HMGB1 is dependent on its redox state","volume":"168","author":"Shin","year":"2025","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib206","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.bbrc.2008.08.108","article-title":"Age-dependent change of HMGB1 and DNA double-strand break accumulation in mouse brain","volume":"376","author":"Enokido","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib207","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1523\/JNEUROSCI.3732-10.2011","article-title":"HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration","volume":"31","author":"Gao","year":"2011","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib208","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109419","article-title":"Tau oligomer induced HMGB1 release contributes to cellular senescence and neuropathology linked to Alzheimer's disease and frontotemporal dementia","volume":"36","author":"Gaikwad","year":"2021","journal-title":"Cell Rep"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib209","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152922","article-title":"Modulation of macrophage polarization and HMGB1-TLR2\/TLR4 cascade plays a crucial role for cardiac remodeling in senescence-accelerated prone mice","volume":"11","author":"Karuppagounder","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100147_bib210","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1161\/01.ATV.0000145573.36113.8a","article-title":"Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines","volume":"24","author":"Kalinina","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib211","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1182\/blood-2002-05-1300","article-title":"Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells","volume":"101","author":"Fiuza","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib212","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2796.2003.01204.x","article-title":"High mobility group 1 B-box mediates activation of human endothelium","volume":"254","author":"Treutiger","year":"2003","journal-title":"J Intern Med"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100147_bib213","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024397","article-title":"Activation of the high mobility group box 1\/receptor for advanced glycation endproducts\/NOD-like receptor family pyrin domain-containing 3 axis under chronic intermittent hypoxia induction promotes the progression of atherosclerosis in ApoE(-\/-) mice","volume":"12","author":"Tan","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib214","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12933-021-01304-8","article-title":"Association between carotid plaque vulnerability and high mobility group box-1 serum levels in a diabetic population","volume":"20","author":"Biscetti","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.pharmr.2026.100147_bib215","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111417","article-title":"The potential role of the adipokine HMGB1 in obesity and insulin resistance: novel effects on adipose tissue biology","volume":"536","author":"Guzman-Ruiz","year":"2021","journal-title":"Mol Cell Endocrinol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100147_bib216","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1161\/ATVBAHA.120.314599","article-title":"High-mobility group box-1 is associated with obesity, inflammation, and subclinical cardiovascular risk among young adults: a longitudinal cohort study","volume":"40","author":"Chen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmr.2026.100147_bib217","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.mce.2017.06.012","article-title":"HMGB1, an innate alarmin, plays a critical role in chronic inflammation of adipose tissue in obesity","volume":"454","author":"Zhang","year":"2017","journal-title":"Mol Cell Endocrinol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100147_bib218","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/oby.21549","article-title":"HMGB1 is secreted by 3T3-L1 adipocytes through JNK signaling and the secretion is partially inhibited by adiponectin","volume":"24","author":"Shimizu","year":"2016","journal-title":"Obesity"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100147_bib219","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1097\/CCM.0b013e318180b3ba","article-title":"Effects of hyperglycemia and insulin therapy on high mobility group box 1 in endotoxin-induced acute lung injury in a rat model","volume":"36","author":"Hagiwara","year":"2008","journal-title":"Crit Care Med"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063073","article-title":"Identification and characterization of the direct interaction between methotrexate (MTX) and high-mobility group box 1 (HMGB1) protein","volume":"8","author":"Kuroiwa","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100147_bib221","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/17460441.2020.1790523","article-title":"Phage display technology for target determination of small-molecule therapeutics: an update","volume":"15","author":"Takakusagi","year":"2020","journal-title":"Expert Opin Drug Discov"},{"issue":"1\u20132","key":"10.1016\/j.pharmr.2026.100147_bib222","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11010-016-2783-1","article-title":"Methotrexate affects HMGB1 expression in rheumatoid arthritis, and the downregulation of HMGB1 prevents rheumatoid arthritis progression","volume":"420","author":"Li","year":"2016","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.pharmr.2026.100147_bib223","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1285455","article-title":"Immunomodulatory roles of metalloproteinases in rheumatoid arthritis","volume":"14","author":"Bian","year":"2023","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib224","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.18632\/aging.102955","article-title":"Metformin inhibits high glucose-induced smooth muscle cell proliferation and migration","volume":"12","author":"Zhou","year":"2020","journal-title":"Aging"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib225","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000495310","article-title":"Glycyrrhizin, a high-mobility group box 1 inhibitor, improves lipid metabolism and suppresses vascular inflammation in apolipoprotein E knockout mice","volume":"55","author":"Ding","year":"2018","journal-title":"J Vasc Res"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib226","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1159\/000485045","article-title":"High mobility group box 1 inhibitor glycyrrhizic acid attenuates kidney injury in streptozotocin-induced diabetic rats","volume":"42","author":"Zhang","year":"2017","journal-title":"Kidney Blood Press Res"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100147_bib227","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113252","article-title":"APOE4-promoted gliosis and degeneration in tauopathy are ameliorated by pharmacological inhibition of HMGB1 release","volume":"42","author":"Koutsodendris","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.pharmr.2026.100147_bib228","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115234","article-title":"Co-treatment with natural HMGB1 inhibitor glycyrrhizin exerts neuroprotection and reverses Parkinson's disease-like pathology in zebrafish","volume":"292","author":"Ren","year":"2022","journal-title":"J Ethnopharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib229","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00018-018-2943-4","article-title":"An insight into gut microbiota and its functionalities","volume":"76","author":"Adak","year":"2019","journal-title":"Cell Mol Life Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib230","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41422-020-0332-7","article-title":"Interaction between microbiota and immunity in health and disease","volume":"30","author":"Zheng","year":"2020","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib231","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41392-022-00974-4","article-title":"Microbiota in health and diseases","volume":"7","author":"Hou","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100147_bib232","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1080\/10408398.2020.1867054","article-title":"Gut microbiota and aging","volume":"62","author":"Ling","year":"2022","journal-title":"Crit Rev Food Sci Nutr"},{"key":"10.1016\/j.pharmr.2026.100147_bib233","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107334","article-title":"Microbiota alterations associated with vascular diseases: postbiotics as a next-generation magic bullet for gut-vascular axis","volume":"207","author":"Flori","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pharmr.2026.100147_bib234","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.796288","article-title":"Gut microbiota interact with the brain through systemic chronic inflammation: implications on neuroinflammation, neurodegeneration, and aging","volume":"13","author":"Mou","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100147_bib235","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1093\/brain\/awab156","article-title":"The role of gut dysbiosis in Parkinson's disease: mechanistic insights and therapeutic options","volume":"144","author":"Wang","year":"2021","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib236","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-023-01619-w","article-title":"Drug-microbiota interactions: an emerging priority for precision medicine","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib237","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3390\/biomedicines12010194","article-title":"Mechanisms and clinical implications of human gut microbiota-drug interactions in the precision medicine era","volume":"12","author":"Wang","year":"2024","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib238","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.chom.2020.12.008","article-title":"Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation","volume":"29","author":"Nayak","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.pharmr.2026.100147_bib239","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.01202","article-title":"Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis","volume":"2","author":"Scher","year":"2013","journal-title":"Elife"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib240","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/acr2.11673","article-title":"Treatment for rheumatoid arthritis associated with alterations in the gastrointestinal microbiota","volume":"6","author":"Andreasson","year":"2024","journal-title":"ACR Open Rheumatol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100147_bib241","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/nm.3914","article-title":"The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment","volume":"21","author":"Zhang","year":"2015","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib242","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13073-016-0299-7","article-title":"An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis","volume":"8","author":"Chen","year":"2016","journal-title":"Genome Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib243","first-page":"1513","article-title":"Substantial decreases in the number and diversity of microbiota during chemotherapy-induced gastrointestinal mucositis in a rat model","volume":"23","author":"Fijlstra","year":"2015","journal-title":"Support Care Cancer"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100147_bib244","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1021\/acs.jproteome.0c00230","article-title":"A two-way interaction between methotrexate and the gut microbiota of male Sprague-Dawley rats","volume":"19","author":"Letertre","year":"2020","journal-title":"J Proteome Res"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib245","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/nutrit\/nuv004","article-title":"Obesity and the gastrointestinal microbiota: a review of associations and mechanisms","volume":"73","author":"Graham","year":"2015","journal-title":"Nutr Rev"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib246","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13601-y","article-title":"Gut microbiome alterations in Alzheimer's disease","volume":"7","author":"Vogt","year":"2017","journal-title":"Sci Rep"},{"issue":"20","key":"10.1016\/j.pharmr.2026.100147_bib247","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252011272","article-title":"Novelties on neuroinflammation in Alzheimer's disease: focus on gut and oral microbiota involvement","volume":"25","author":"Popescu","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib248","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1007\/s12035-024-04370-7","article-title":"Gut microbiota-induced modulation of the central nervous system function in Parkinson's disease through the gut-brain axis and short-chain fatty acids","volume":"62","author":"Ni","year":"2025","journal-title":"Mol Neurobiol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib249","doi-asserted-by":"crossref","DOI":"10.1038\/nutd.2014.23","article-title":"Adiposity, gut microbiota and faecal short chain fatty acids are linked in adult humans","volume":"4","author":"Fernandes","year":"2014","journal-title":"Nutr Diabetes"},{"issue":"7606","key":"10.1016\/j.pharmr.2026.100147_bib250","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nature18309","article-title":"Acetate mediates a microbiome-brain-\u03b2-cell axis to promote metabolic syndrome","volume":"534","author":"Perry","year":"2016","journal-title":"Nature"},{"issue":"7612","key":"10.1016\/j.pharmr.2026.100147_bib251","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature18646","article-title":"Human gut microbes impact host serum metabolome and insulin sensitivity","volume":"535","author":"Pedersen","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2026.100147_bib252","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.atherosclerosis.2018.11.038","article-title":"The intestinal microbiota associated with cardiac valve calcification differs from that of coronary artery disease","volume":"284","author":"Liu","year":"2019","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100147_bib253","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1136\/gutjnl-2024-331880","article-title":"Puerarin alleviates atherosclerosis via the inhibition of Prevotella copri and its trimethylamine production","volume":"73","author":"Li","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.pharmr.2026.100147_bib254","article-title":"The gut microbiome shapes pharmacology and treatment outcomes for a key anti-inflammatory therapy","author":"Villa Soto","year":"2025","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib255","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100147_bib256","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.cell.2022.04.004","article-title":"Atherosclerosis: recent developments","volume":"185","author":"Bjorkegren","year":"2022","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100147_bib257","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1080\/14728222.2023.2288272","article-title":"Lipid-laden foam cells in the pathology of atherosclerosis: shedding light on new therapeutic targets","volume":"27","author":"Galindo","year":"2023","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib258","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41392-022-00955-7","article-title":"Inflammation and atherosclerosis: signaling pathways and therapeutic intervention","volume":"7","author":"Kong","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"7855","key":"10.1016\/j.pharmr.2026.100147_bib259","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","article-title":"The changing landscape of atherosclerosis","volume":"592","author":"Libby","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2026.100147_bib260","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fcvm.2017.00086","article-title":"Mechanisms and consequences of defective efferocytosis in atherosclerosis","volume":"4","author":"Yurdagul","year":"2017","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib261","doi-asserted-by":"crossref","DOI":"10.1186\/ar2109","article-title":"Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk","volume":"9","author":"Chan","year":"2007","journal-title":"Arthritis Res Ther"},{"issue":"25","key":"10.1016\/j.pharmr.2026.100147_bib262","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.pharmr.2026.100147_bib263","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehw024","article-title":"Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100147_bib264","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.3390\/ijms26135919","article-title":"MicroRNA-mediated regulation of vascular endothelium: from pro-inflammation to atherosclerosis","volume":"26","author":"Silva","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib265","first-page":"1973","article-title":"MicroRNA-181b regulates NF-kappaB-mediated vascular inflammation","volume":"122","author":"Sun","year":"2012","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100147_bib266","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1042\/CS20110625","article-title":"AMP-activated protein kinase, stress responses and cardiovascular diseases","volume":"122","author":"Wang","year":"2012","journal-title":"Clin Sci (Lond)"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib267","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1161\/01.ATV.0000221230.08596.98","article-title":"AMP-activated protein kinase is involved in endothelial NO synthase activation in response to shear stress","volume":"26","author":"Zhang","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100147_bib268","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1007\/s11427-017-9240-2","article-title":"Role of AMPK in atherosclerosis via autophagy regulation","volume":"61","author":"Ou","year":"2018","journal-title":"Sci China Life Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib269","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12933-025-02586-y","article-title":"N(epsilon)-carboxyethyl-lysin influences atherosclerotic plaque stability through ZKSCAN3 acetylation-regulated macrophage autophagy via the RAGE\/LKB1\/AMPK1\/SIRT1 pathway","volume":"24","author":"Liu","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.pharmr.2026.100147_bib270","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101514","article-title":"Defective AMPK regulation of cholesterol metabolism accelerates atherosclerosis by promoting HSPC mobilization and myelopoiesis","volume":"61","author":"Lee","year":"2022","journal-title":"Mol Metab"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib271","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/CIRCRESAHA.115.306361","article-title":"Vascular smooth muscle cells in atherosclerosis","volume":"118","author":"Bennett","year":"2016","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib272","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.atherosclerosis.2008.12.016","article-title":"Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients","volume":"205","author":"Yan","year":"2009","journal-title":"Atherosclerosis"},{"issue":"7341","key":"10.1016\/j.pharmr.2026.100147_bib273","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature09922","article-title":"Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease","volume":"472","author":"Wang","year":"2011","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100147_bib274","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1109400","article-title":"Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk","volume":"368","author":"Tang","year":"2013","journal-title":"N Engl J Med"},{"issue":"9313","key":"10.1016\/j.pharmr.2026.100147_bib275","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","article-title":"Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study","volume":"359","author":"Choi","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib276","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jaad.2004.06.017","article-title":"Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis","volume":"52","author":"Prodanovich","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.pharmr.2026.100147_bib277","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152031","article-title":"Methotrexate use reduces mortality risk in rheumatoid arthritis: a systematic review and meta-analysis of cohort studies","volume":"55","author":"Xu","year":"2022","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib278","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.21618","article-title":"Comparison of cardiovascular events among users of different classes of antihypertension medications: a systematic review and network meta-analysis","volume":"3","author":"Wei","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib279","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/2047487313480435","article-title":"Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials","volume":"20","author":"Naci","year":"2013","journal-title":"Eur J Prev Cardiol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100147_bib280","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100147_bib281","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jchf.2016.08.001","article-title":"Hypertension, obesity, diabetes, and heart failure-free survival: the Cardiovascular Disease Lifetime Risk Pooling Project","volume":"4","author":"Ahmad","year":"2016","journal-title":"JACC Heart Fail"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib282","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102411","article-title":"Unraveling the complex pathophysiology of heart failure: insights into the role of renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS)","volume":"49","author":"Maryam","year":"2024","journal-title":"Curr Probl Cardiol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib283","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s10741-019-09806-0","article-title":"Pathogenesis and pathophysiology of heart failure with reduced ejection fraction: translation to human studies","volume":"24","author":"Ge","year":"2019","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.pharmr.2026.100147_bib284","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.906272","article-title":"Endothelial dysfunction in heart failure with preserved ejection fraction: what are the experimental proofs?","volume":"13","author":"Cornuault","year":"2022","journal-title":"Front Physiol"},{"key":"10.1016\/j.pharmr.2026.100147_bib285","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.606740","article-title":"Nitric oxide and mechano-electrical transduction in cardiomyocytes","volume":"11","author":"Boycott","year":"2020","journal-title":"Front Physiol"},{"key":"10.1016\/j.pharmr.2026.100147_bib286","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1111721","article-title":"Coronary microvascular dysfunction: a review of recent progress and clinical implications","volume":"10","author":"Rehan","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"19","key":"10.1016\/j.pharmr.2026.100147_bib287","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1161\/CIRCULATIONAHA.106.649244","article-title":"Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes","volume":"114","author":"Yang","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2026.100147_bib288","article-title":"Role of cardiac A(2A) receptors under normal and pathophysiological conditions","volume":"11","author":"Boknik","year":"2020","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib289","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41569-023-00946-3","article-title":"The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases","volume":"21","author":"Toldo","year":"2024","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib290","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/ATVBAHA.111.226852","article-title":"Regulation of macrophage function by adenosine","volume":"32","author":"Hasko","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100147_bib291","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","article-title":"Cardiac energy metabolism in heart failure","volume":"128","author":"Lopaschuk","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmr.2026.100147_bib292","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2025.1638515","article-title":"Isoform-specific roles of AMP-activated protein kinase in cardiac physiology and pathophysiology","volume":"12","author":"Rakoubian","year":"2025","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100147_bib293","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1080\/15384101.2023.2167949","article-title":"Emerging role of mitophagy in heart failure: from molecular mechanism to targeted therapy","volume":"22","author":"Liu","year":"2023","journal-title":"Cell Cycle"},{"key":"10.1016\/j.pharmr.2026.100147_bib294","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/978-981-15-0602-4_4","article-title":"AMPK and autophagy","volume":"1206","author":"Li","year":"2019","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib295","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41392-025-02493-4","article-title":"mTOR signaling networks: mechanistic insights and translational frontiers in disease therapeutics","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib296","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20181767","article-title":"AMPK: a therapeutic target of heart failure\u2014not only metabolism regulation","volume":"39","author":"Li","year":"2019","journal-title":"Biosci Rep"},{"key":"10.1016\/j.pharmr.2026.100147_bib297","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.freeradbiomed.2021.02.047","article-title":"AMP-activated protein kinase: a remarkable contributor to preserve a healthy heart against ROS injury","volume":"166","author":"Marino","year":"2021","journal-title":"Free Radic Biol Med"},{"issue":"22","key":"10.1016\/j.pharmr.2026.100147_bib298","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1161\/CIRCULATIONAHA.122.063327","article-title":"Endothelin-1, outcomes in patients with heart failure and reduced ejection fraction, and effects of dapagliflozin: findings from DAPA-HF","volume":"147","author":"Yeoh","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2026.100147_bib299","article-title":"JAK\/STAT3 signaling in cardiac fibrosis: a promising therapeutic target","volume":"15","author":"Jiang","year":"2024","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib300","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4196\/kjpp.2024.28.3.285","article-title":"Fibroblast-derived interleukin-6 exacerbates adverse cardiac remodeling after myocardial infarction","volume":"28","author":"Li","year":"2024","journal-title":"Korean J Physiol Pharmacol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100147_bib301","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jchf.2023.06.031","article-title":"Interleukin-6 in patients with heart failure and preserved ejection fraction","volume":"11","author":"Alogna","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.pharmr.2026.100147_bib302","article-title":"Loganin inhibits angiotensin II-induced cardiac hypertrophy through the JAK2\/STAT3 and NF-kappaB signaling pathways","volume":"12","author":"Xu","year":"2021","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100147_bib303","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1111\/jcmm.17267","article-title":"Periplocymarin alleviates pathological cardiac hypertrophy via inhibiting the JAK2\/STAT3 signalling pathway","volume":"26","author":"Fan","year":"2022","journal-title":"J Cell Mol Med"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100147_bib304","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.7150\/ijbs.96489","article-title":"Ruxolitinib-based senomorphic therapy mitigates cardiomyocyte senescence in septic cardiomyopathy by inhibiting the JAK2\/STAT3 signaling pathway","volume":"20","author":"Yang","year":"2024","journal-title":"Int J Biol Sci"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib305","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/eurjhf\/hfq231","article-title":"Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure","volume":"13","author":"Wang","year":"2011","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib306","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00392-011-0409-x","article-title":"HMGB1 is an independent predictor of death and heart transplantation in heart failure","volume":"101","author":"Volz","year":"2012","journal-title":"Clin Res Cardiol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100147_bib307","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1111\/jcmm.12399","article-title":"HMGB1 mediates hyperglycaemia-induced cardiomyocyte apoptosis via ERK\/Ets-1 signalling pathway","volume":"18","author":"Wang","year":"2014","journal-title":"J Cell Mol Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib308","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s44325-026-00119-4","article-title":"Scoping review of preclinical and clinical studies on the role of HMGB1 in heart disease","volume":"3","author":"Mao","year":"2026","journal-title":"NPJ Cardiovasc Health"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib309","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijcard.2010.12.016","article-title":"Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure","volume":"157","author":"Sandek","year":"2012","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib310","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41569-018-0108-7","article-title":"Dietary metabolism, the gut microbiome, and heart failure","volume":"16","author":"Tang","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib311","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002314","article-title":"Choline diet and its gut microbe-derived metabolite, trimethylamine N-oxide, exacerbate pressure overload-induced heart failure","volume":"9","author":"Organ","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100147_bib312","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014661","article-title":"Heart failure risk associated with rheumatoid arthritis-related chronic inflammation","volume":"9","author":"Ahlers","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100147_bib313","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.3899\/jrheum.100979","article-title":"The influence of rheumatoid arthritis disease characteristics on heart failure","volume":"38","author":"Myasoedova","year":"2011","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib314","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ahj.2005.02.040","article-title":"The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure","volume":"151","author":"Gong","year":"2006","journal-title":"Am Heart J"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100147_bib315","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.cardfail.2009.06.439","article-title":"The effects of METhotrexate therapy on the physical capacity of patients with ISchemic heart failure: a randomized double-blind, placebo-controlled trial (METIS trial)","volume":"15","author":"Moreira","year":"2009","journal-title":"J Card Fail"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib316","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41574-020-00443-4","article-title":"Type 1 diabetes mellitus as a disease of the beta-cell (do not blame the immune system?)","volume":"17","author":"Roep","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib317","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41574-025-01114-y","article-title":"Insulin resistance in type 2 diabetes mellitus","volume":"21","author":"Accili","year":"2025","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100147_bib318","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.3390\/cells10123328","article-title":"Lipotoxicity and \u03b2-cell failure in type 2 diabetes: oxidative stress linked to NADPH oxidase and ER stress","volume":"10","author":"Vilas-Boas","year":"2021","journal-title":"Cells"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100147_bib319","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.3390\/ijms21176275","article-title":"Pathophysiology of type 2 diabetes mellitus","volume":"21","author":"Galicia-Garcia","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib320","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3727\/096368910X491806","article-title":"Adenosine A(2A) agonist administration improves islet transplant outcome: evidence for the role of innate immunity in islet graft rejection","volume":"19","author":"Chhabra","year":"2010","journal-title":"Cell Transplant"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib321","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.cmet.2012.04.018","article-title":"Adenosine signaling promotes regeneration of pancreatic \u03b2 cells in vivo","volume":"15","author":"Andersson","year":"2012","journal-title":"Cell Metab"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100147_bib322","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41574-025-01142-8","article-title":"Adipose tissue ageing: implications for metabolic health and lifespan","volume":"21","author":"Wang","year":"2025","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib323","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13098-023-01022-z","article-title":"Causal relationship between insulin resistance and sarcopenia","volume":"15","author":"Liu","year":"2023","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib324","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/joim.12071","article-title":"Ectopic lipid storage and insulin resistance: a harmful relationship","volume":"274","author":"Boren","year":"2013","journal-title":"J Intern Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib325","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cmet.2014.09.018","article-title":"Metformin: From mechanisms of action to therapies","volume":"20","author":"Foretz","year":"2014","journal-title":"Cell Metab"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100147_bib326","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1007\/s00125-020-05243-z","article-title":"Evaluating the impact of AMPK activation, a target of metformin, on risk of cardiovascular diseases and cancer in the UK Biobank: a Mendelian randomisation study","volume":"63","author":"Luo","year":"2020","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100147_bib327","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.tem.2012.06.003","article-title":"New insights into ER stress-induced insulin resistance","volume":"23","author":"Flamment","year":"2012","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib328","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1210\/er.2007-0015","article-title":"The role for endoplasmic reticulum stress in diabetes mellitus","volume":"29","author":"Eizirik","year":"2008","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib329","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1146\/annurev-biochem-072909-095555","article-title":"Endoplasmic reticulum stress and type 2 diabetes","volume":"81","author":"Back","year":"2012","journal-title":"Annu Rev Biochem"},{"issue":"Suppl 1","key":"10.1016\/j.pharmr.2026.100147_bib330","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14007","article-title":"An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines","volume":"22","author":"Selby","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib331","article-title":"Mechanisms linking inflammation to insulin resistance","volume":"2015","author":"Chen","year":"2015","journal-title":"Int J Endocrinol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib332","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/db16-1250","article-title":"Repurposed JAK1\/JAK2 inhibitor reverses established autoimmune insulitis in NOD mice","volume":"66","author":"Trivedi","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2026.100147_bib333","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2026.1769497","article-title":"HMGB1: a key molecule linking chronic inflammation to complications in type 2 diabetes mellitus and a target for exercise intervention","volume":"17","author":"Pengyu","year":"2026","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib334","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2340487","article-title":"Effects of Prevotella copri on insulin, gut microbiota and bile acids","volume":"16","author":"Gong","year":"2024","journal-title":"Gut Microbes"},{"issue":"24","key":"10.1016\/j.pharmr.2026.100147_bib335","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1001\/jama.2011.878","article-title":"Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis","volume":"305","author":"Solomon","year":"2011","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib336","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235637","article-title":"Effect of methotrexate use on the development of type 2 diabetes in rheumatoid arthritis patients: a systematic review and meta-analysis","volume":"15","author":"Baghdadi","year":"2020","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib337","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.semarthrit.2020.04.005","article-title":"Incident diabetes associated with hydroxychloroquine, methotrexate, biologics and glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis","volume":"50","author":"Xie","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100147_bib338","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.3390\/jcm11082109","article-title":"Risk of new-onset diabetes mellitus associated with antirheumatic drugs in patients with rheumatoid arthritis: a nationwide population study","volume":"11","author":"Nam","year":"2022","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100147_bib339","article-title":"Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus","volume":"12","author":"Madsen","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib340","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41569-024-01111-0","article-title":"Apolipoprotein B-containing lipoproteins in atherogenesis","volume":"22","author":"Boren","year":"2025","journal-title":"Nat Rev Cardiol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100147_bib341","doi-asserted-by":"crossref","first-page":"771","DOI":"10.5551\/jat.RV17023","article-title":"Pathophysiology of diabetic dyslipidemia","volume":"25","author":"Hirano","year":"2018","journal-title":"J Atheroscler Thromb"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100147_bib342","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1161\/ATVBAHA.112.300133","article-title":"High-density lipoprotein function, dysfunction, and reverse cholesterol transport","volume":"32","author":"Fisher","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib343","first-page":"595","article-title":"The atherogenic dyslipidemia complex and novel approaches to cardiovascular disease prevention in diabetes","volume":"34","author":"Stahel","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.pharmr.2026.100147_bib344","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.117545","article-title":"Modification of lipoprotein metabolism and function driving atherogenesis in diabetes","volume":"394","author":"Luciani","year":"2024","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100147_bib345","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1194\/jlr.R025882","article-title":"AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases","volume":"53","author":"Srivastava","year":"2012","journal-title":"J Lipid Res"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib346","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s11892-024-01542-6","article-title":"Metabolic dysfunction-associated steatotic liver disease and atherosclerosis","volume":"24","author":"Castillo-Nunez","year":"2024","journal-title":"Curr Diab Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib347","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12944-021-01585-8","article-title":"A new phenotypic classification system for dyslipidemias based on the standard lipid panel","volume":"20","author":"Sampson","year":"2021","journal-title":"Lipids Health Dis"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100147_bib348","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136564","article-title":"Plasma HMGB-1 levels in subjects with obesity and type 2 diabetes: a cross-sectional study in China","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100147_bib349","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1161\/ATVBAHA.120.315189","article-title":"HMGB1 (high-mobility group box-1): a common link determining the consequences of tissue injury, sterile\/microbial and low-grade chronic inflammation","volume":"40","author":"Ghosh","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib350","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/HEP.0000000000000938","article-title":"An integrated analysis of bile acid metabolism in humans with severe obesity","volume":"81","author":"Aydin","year":"2025","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib351","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3390\/microorganisms9071461","article-title":"Subfractional spectrum of serum lipoproteins and gut microbiota composition in healthy individuals","volume":"9","author":"Kashtanova","year":"2021","journal-title":"Microorganisms"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib352","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00296-020-04756-5","article-title":"Similar lipid level changes in early rheumatoid arthritis patients following 1-year treat-to-target strategy with adalimumab plus methotrexate versus placebo plus methotrexate: secondary analyses from the randomized controlled OPERA trial","volume":"41","author":"Masic","year":"2021","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib353","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.bbamcr.2010.09.015","article-title":"Annexin A6-linking Ca(2+) signaling with cholesterol transport","volume":"1813","author":"Enrich","year":"2011","journal-title":"Biochim Biophys Acta"},{"issue":"23","key":"10.1016\/j.pharmr.2026.100147_bib354","doi-asserted-by":"crossref","first-page":"7059","DOI":"10.3390\/jcm11237059","article-title":"Annexin A6 polymorphism is associated with pro-atherogenic lipid profiles and with the downregulation of methotrexate on anti-atherogenic lipid profiles in psoriasis","volume":"11","author":"Zhang","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib355","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-021-02715-4","article-title":"The difference of lipid profiles between psoriasis with arthritis and psoriasis without arthritis and sex-specific downregulation of methotrexate on the apolipoprotein B\/apolipoprotein A-1 ratio","volume":"24","author":"Wang","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib356","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3390\/jcm9040910","article-title":"Methotrexate decreases the level of PCSK9\u2014a novel indicator of the risk of proatherogenic lipid profile in psoriasis. The preliminary data","volume":"9","author":"Krahel","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.pharmr.2026.100147_bib357","doi-asserted-by":"crossref","DOI":"10.1177\/10742484221100107","article-title":"A comprehensive review of PCSK9 inhibitors","volume":"27","author":"Coppinger","year":"2022","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib358","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/CIRCRESAHA.121.318082","article-title":"Pathophysiology of hypertension: The mosaic theory and beyond","volume":"128","author":"Harrison","year":"2021","journal-title":"Circ Res"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib359","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/HYPERTENSIONAHA.123.21369","article-title":"Salt-sensitive hypertension and the kidney","volume":"81","author":"Nishimoto","year":"2024","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib360","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1161\/CIRCRESAHA.121.318061","article-title":"Arterial stiffness and cardiovascular risk in hypertension","volume":"128","author":"Boutouyrie","year":"2021","journal-title":"Circ Res"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100147_bib361","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1161\/HYPERTENSIONAHA.124.21355","article-title":"Immune mechanisms in hypertension","volume":"81","author":"Harrison","year":"2024","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib362","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1748-1716.2010.02218.x","article-title":"Adenosine elicits an eNOS-independent reduction in arterial blood pressure in conscious mice that involves adenosine A2A receptors","volume":"203","author":"Andersen","year":"2011","journal-title":"Acta Physiol"},{"issue":"5-6","key":"10.1016\/j.pharmr.2026.100147_bib363","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.lfs.2011.06.003","article-title":"Adenosine A(2A)R modulates cardiovascular function by activating ERK1\/2 signal in the rostral ventrolateral medulla of acute myocardial ischemic rats","volume":"89","author":"Jiang","year":"2011","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmr.2026.100147_bib364","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1275952","article-title":"Adenosine A(2A) receptors in the rostral ventrolateral medulla participate in blood pressure decrease with electroacupuncture in hypertensive rats","volume":"10","author":"Guo","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"12 Pt 2","key":"10.1016\/j.pharmr.2026.100147_bib365","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1097\/00004872-199917121-00032","article-title":"Adenosine mediates nitric oxide-independent renal vasodilation by activation of A2A receptors","volume":"17","author":"Rump","year":"1999","journal-title":"J Hypertens"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib366","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/HYPERTENSIONAHA.108.123570","article-title":"Inhibition of the adenosine2A receptor-epoxyeicosatrienoic acid pathway renders Dahl salt-resistant rats hypertensive","volume":"54","author":"Liclican","year":"2009","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib367","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0022-3565(25)20893-X","article-title":"A1 and A2 adenosine receptor activation inhibits and stimulates renin secretion of rat renal cortical slices","volume":"232","author":"Churchill","year":"1985","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100147_bib368","doi-asserted-by":"crossref","first-page":"F1209","DOI":"10.1152\/ajprenal.00710.2012","article-title":"Adenosine inhibits renin release from juxtaglomerular cells via an A1 receptor-TRPC-mediated pathway","volume":"305","author":"Ortiz-Capisano","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib369","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0014-5793(98)01705-0","article-title":"AMP-activated protein kinase phosphorylation of endothelial NO synthase","volume":"443","author":"Chen","year":"1999","journal-title":"FEBS Lett"},{"issue":"34","key":"10.1016\/j.pharmr.2026.100147_bib370","doi-asserted-by":"crossref","first-page":"31629","DOI":"10.1074\/jbc.M212831200","article-title":"Direct activation of AMP-activated protein kinase stimulates nitric oxide synthesis in human aortic endothelial cells","volume":"278","author":"Morrow","year":"2003","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib371","doi-asserted-by":"crossref","first-page":"496","DOI":"10.2337\/diabetes.55.02.06.db05-1064","article-title":"Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase","volume":"55","author":"Davis","year":"2006","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100147_bib372","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1759720X17719850","article-title":"Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study","volume":"9","author":"Mangoni","year":"2017","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100147_bib373","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1089\/ars.2020.8103","article-title":"Roles of perivascular adipose tissue in hypertension and atherosclerosis","volume":"34","author":"Hu","year":"2021","journal-title":"Antioxid Redox Signal"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib374","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1161\/HYPERTENSIONAHA.110.168906","article-title":"Inhibition of the AMP-activated protein kinase-\u03b12 accentuates agonist-induced vascular smooth muscle contraction and high blood pressure in mice","volume":"57","author":"Wang","year":"2011","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib375","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3390\/biomedicines9070781","article-title":"Inflammatory mechanisms contributing to endothelial dysfunction","volume":"9","author":"Theofilis","year":"2021","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib376","doi-asserted-by":"crossref","first-page":"R1169","DOI":"10.1152\/ajpregu.00071.2011","article-title":"Angiotensin II utilizes Janus kinase 2 in hypertension, but not in the physiological control of blood pressure, during low-salt intake","volume":"301","author":"Banes-Berceli","year":"2011","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100147_bib377","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/aps.2014.54","article-title":"P300-dependent STAT3 acetylation is necessary for angiotensin II-induced pro-fibrotic responses in renal tubular epithelial cells","volume":"35","author":"Ni","year":"2014","journal-title":"Acta Pharmacol Sin"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100147_bib378","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1161\/CIRCRESAHA.116.310480","article-title":"T-cell mineralocorticoid receptor controls blood pressure by regulating interferon-gamma","volume":"120","author":"Sun","year":"2017","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib379","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1161\/HYPERTENSIONAHA.116.07493","article-title":"Interleukin-17A regulates renal sodium transporters and renal injury in angiotensin II-induced hypertension","volume":"68","author":"Norlander","year":"2016","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100147_bib380","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41577-019-0160-5","article-title":"Immune mechanisms of hypertension","volume":"19","author":"Drummond","year":"2019","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib381","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1007\/s11033-011-1106-6","article-title":"High mobility group box-1 induces migration of vascular smooth muscle cells via TLR4-dependent PI3K\/Akt pathway activation","volume":"39","author":"Yang","year":"2012","journal-title":"Mol Biol Rep"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib382","doi-asserted-by":"crossref","first-page":"231","DOI":"10.14336\/AD.2018.0510","article-title":"Involvement of the miR-181b-5p\/HMGB1 pathway in Ang II-induced phenotypic transformation of smooth muscle cells in hypertension","volume":"10","author":"Li","year":"2019","journal-title":"Aging Dis"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib383","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4196\/kjpp.2022.26.5.389","article-title":"HMGB1 increases RAGE expression in vascular smooth muscle cells via ERK and p-38 MAPK-dependent pathways","volume":"26","author":"Jang","year":"2022","journal-title":"Korean J Physiol Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib384","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.yexcr.2015.05.011","article-title":"Angiotensin II-induced hypertensive renal inflammation is mediated through HMGB1-TLR4 signaling in rat tubulo-epithelial cells","volume":"335","author":"Nair","year":"2015","journal-title":"Exp Cell Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib385","doi-asserted-by":"crossref","first-page":"F69","DOI":"10.1152\/ajprenal.00484.2014","article-title":"HMGB1 exacerbates renal tubulointerstitial fibrosis through facilitating M1 macrophage phenotype at the early stage of obstructive injury","volume":"308","author":"Tian","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3-4","key":"10.1016\/j.pharmr.2026.100147_bib386","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2119\/2007-00107.Bruchfeld","article-title":"High mobility group box protein-1 correlates with renal function in chronic kidney disease (CKD)","volume":"14","author":"Bruchfeld","year":"2008","journal-title":"Mol Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib387","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12974-019-1673-3","article-title":"HMGB1\/RAGE axis mediates stress-induced RVLM neuroinflammation in mice via impairing mitophagy flux in microglia","volume":"17","author":"Zhang","year":"2020","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.pharmr.2026.100147_bib388","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3389\/fphys.2017.00593","article-title":"The temporal relationship between arterial stiffening and blood pressure is modified by methotrexate treatment in patients with rheumatoid arthritis","volume":"8","author":"Woodman","year":"2017","journal-title":"Front Physiol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib389","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/RHU.0000000000000736","article-title":"Initiation of disease-modifying therapies in rheumatoid arthritis is associated with changes in blood pressure","volume":"24","author":"Baker","year":"2018","journal-title":"J Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib390","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1093\/rheumatology\/keae604","article-title":"Blood pressure changes during methotrexate treatment: results from a randomized placebo-controlled trial among patients with cardiovascular risk","volume":"64","author":"Cui","year":"2025","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib391","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2025.2539311","article-title":"A controlled comparative study of the effects of methotrexate and pharmacogenetic factors on arterial blood pressure and arterial stiffness in patients with rheumatoid arthritis","volume":"57","author":"Mangoni","year":"2025","journal-title":"Ann Med"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib392","doi-asserted-by":"crossref","first-page":"C375","DOI":"10.1152\/ajpcell.00379.2020","article-title":"Adipose tissue inflammation and metabolic dysfunction in obesity","volume":"320","author":"Kawai","year":"2021","journal-title":"Am J Physiol Cell Physiol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib393","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3390\/biomedicines12071474","article-title":"Thermogenic fat as a new obesity management tool: from pharmaceutical reagents to cell therapies","volume":"12","author":"Cheng","year":"2024","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib394","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11154-021-09636-2","article-title":"Leptin, the brain and energy homeostasis: from an apparently simple to a highly complex neuronal system","volume":"23","author":"Maffei","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.pharmr.2026.100147_bib395","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.571731","article-title":"Gut microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes","volume":"11","author":"Scheithauer","year":"2020","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100147_bib396","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.cmet.2023.08.001","article-title":"Deciphering the decline of metabolic elasticity in aging and obesity","volume":"35","author":"Zhou","year":"2023","journal-title":"Cell Metab"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100147_bib397","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1128\/MCB.00192-09","article-title":"Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue","volume":"29","author":"Halberg","year":"2009","journal-title":"Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib398","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1146\/annurev-physiol-060721-092930","article-title":"Adipose tissue fibrosis in obesity: etiology and challenges","volume":"84","author":"Marcelin","year":"2022","journal-title":"Annu Rev Physiol"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100147_bib399","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1128\/MCB.00244-16","article-title":"AMPK phosphorylates desnutrin\/ATGL and hormone-sensitive lipase to regulate lipolysis and fatty acid oxidation within adipose tissue","volume":"36","author":"Kim","year":"2016","journal-title":"Mol Cell Biol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib400","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1042\/BCJ20240003","article-title":"AMP-activated protein kinase activation suppresses leptin expression independently of adipogenesis in primary murine adipocytes","volume":"481","author":"Bustraan","year":"2024","journal-title":"Biochem J"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100147_bib401","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/nm788","article-title":"Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase","volume":"8","author":"Yamauchi","year":"2002","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib402","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cmet.2007.06.003","article-title":"Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake","volume":"6","author":"Kubota","year":"2007","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib403","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00795-007-0366-7","article-title":"Pathophysiological significance of adiponectin","volume":"40","author":"Nishida","year":"2007","journal-title":"Med Mol Morphol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib404","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2019.34.e7","article-title":"The association of adiponectin and visceral fat with insulin resistance and \u03b2-cell dysfunction","volume":"34","author":"Moon","year":"2019","journal-title":"J Korean Med Sci"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib405","article-title":"Mechanisms of chronic JAK-STAT3-SOCS3 signaling in obesity","volume":"2","author":"Wunderlich","year":"2013","journal-title":"JAKSTAT"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib406","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nm1072","article-title":"Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3","volume":"10","author":"Howard","year":"2004","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib407","doi-asserted-by":"crossref","first-page":"7653","DOI":"10.1038\/s41598-017-07923-0","article-title":"Macrophage JAK2 deficiency protects against high-fat diet-induced inflammation","volume":"7","author":"Desai","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib408","doi-asserted-by":"crossref","first-page":"720","DOI":"10.2337\/db20-0634","article-title":"Deficiency of Stat1 in CD11c(+) cells alters adipose tissue inflammation and improves metabolic dysfunctions in mice fed a high-fat diet","volume":"70","author":"Antony","year":"2021","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib409","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/ibd\/izy364","article-title":"A JAK1 selective kinase inhibitor and tofacitinib affect macrophage activation and function","volume":"25","author":"De Vries","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib410","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1007\/s11033-022-07214-6","volume":"49","author":"Khanaghaei","year":"2022","journal-title":"Mol Biol Rep"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100147_bib411","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/art.39647","article-title":"Changes in body mass related to the initiation of disease-modifying therapies in rheumatoid arthritis","volume":"68","author":"Baker","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib412","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3899\/jrheum.141363","article-title":"Predictors of longterm changes in body mass index in rheumatoid arthritis","volume":"42","author":"Baker","year":"2015","journal-title":"J Rheumatol"},{"issue":"10284","key":"10.1016\/j.pharmr.2026.100147_bib413","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib414","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13024-023-00640-5","article-title":"Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer's disease","volume":"18","author":"Inoue","year":"2023","journal-title":"Mol Neurodegener"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib415","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(19)30153-X","article-title":"New evidence on the management of Lewy body dementia","volume":"19","author":"Taylor","year":"2020","journal-title":"Lancet Neurol"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100147_bib416","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411732","article-title":"Frontotemporal dementia, where do we stand? A narrative review","volume":"24","author":"Antonioni","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib417","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41582-022-00659-0","article-title":"Rapidly progressive dementias\u2014aetiologies, diagnosis and management","volume":"18","author":"Hermann","year":"2022","journal-title":"Nat Rev Neurol"},{"issue":"18","key":"10.1016\/j.pharmr.2026.100147_bib418","doi-asserted-by":"crossref","first-page":"9793","DOI":"10.7150\/thno.118737","article-title":"The pathophysiology of mixed Alzheimer's disease and vascular dementia","volume":"15","author":"Sarhan","year":"2025","journal-title":"Theranostics"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100147_bib419","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000214220","article-title":"Alzheimer disease, vascular disease, and blood-brain barrier permeability biomarkers in middle-aged adults","volume":"105","author":"Edwards","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.pharmr.2026.100147_bib420","doi-asserted-by":"crossref","DOI":"10.1177\/0271678X261437523","article-title":"Neuroinflammation in vascular cognitive impairment and dementia: insights from clinical biomarkers and experimental models","author":"Mizutani","year":"2026","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.pharmr.2026.100147_bib421","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2020.110882","article-title":"Impairment of PGC-1\u03b1-mediated mitochondrial biogenesis precedes mitochondrial dysfunction and Alzheimer's pathology in the 3xTg mouse model of Alzheimer's disease","volume":"133","author":"Singulani","year":"2020","journal-title":"Exp Gerontol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100147_bib422","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1007\/s11064-023-03934-8","article-title":"The role of PGC-1\u03b1-mediated mitochondrial biogenesis in neurons","volume":"48","author":"Chen","year":"2023","journal-title":"Neurochem Res"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100147_bib423","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.3390\/ijms12107199","article-title":"Roles of oxidative stress, apoptosis, PGC-1\u03b1 and mitochondrial biogenesis in cerebral ischemia","volume":"12","author":"Chen","year":"2011","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharmr.2026.100147_bib424","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12974-014-0177-4","article-title":"Metformin attenuates blood-brain barrier disruption in mice following middle cerebral artery occlusion","volume":"11","author":"Liu","year":"2014","journal-title":"J Neuroinflammation"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib425","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.yexmp.2014.09.006","article-title":"Activation of AMPK attenuates lipopolysaccharide-impaired integrity and function of blood-brain barrier in human brain microvascular endothelial cells","volume":"97","author":"Zhao","year":"2014","journal-title":"Exp Mol Pathol"},{"issue":"18","key":"10.1016\/j.pharmr.2026.100147_bib426","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810572","article-title":"Glial cell-mediated neuroinflammation in Alzheimer's disease","volume":"23","author":"Al-Ghraiybah","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"20","key":"10.1016\/j.pharmr.2026.100147_bib427","doi-asserted-by":"crossref","first-page":"7458","DOI":"10.3390\/ijms21207458","article-title":"Activation of STAT3 regulates reactive astrogliosis and neuronal death induced by A\u03b2O neurotoxicity","volume":"21","author":"Toral-Rios","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib428","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1523\/JNEUROSCI.3516-14.2015","article-title":"The JAK\/STAT3 pathway is a common inducer of astrocyte reactivity in Alzheimer's and Huntington's diseases","volume":"35","author":"Ben","year":"2015","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib429","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809665","article-title":"Inhibition of Stat3-mediated astrogliosis ameliorates pathology in an Alzheimer's disease model","volume":"11","author":"Reichenbach","year":"2019","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.pharmr.2026.100147_bib430","doi-asserted-by":"crossref","DOI":"10.1038\/srep31895","article-title":"HMGB1, a pathogenic molecule that induces neurite degeneration via TLR4-MARCKS, is a potential therapeutic target for Alzheimer's disease","volume":"6","author":"Fujita","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib431","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41467-020-14353-6","article-title":"YAP-dependent necrosis occurs in early stages of Alzheimer's disease and regulates mouse model pathology","volume":"11","author":"Tanaka","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib432","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1084\/jem.20180794","article-title":"Microbiome-microglia connections via the gut-brain axis","volume":"216","author":"Abdel-Haq","year":"2019","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib433","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/advances\/nmz127","article-title":"Tryptophan metabolism: a link between the gut microbiota and brain","volume":"11","author":"Gao","year":"2020","journal-title":"Adv Nutr"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib434","doi-asserted-by":"crossref","DOI":"10.1002\/ajmg.b.32959","article-title":"Influence of gut microbiota on the development of most prevalent neurodegenerative dementias and the potential effect of probiotics in elderly: a scoping review","volume":"195","author":"Mateo","year":"2024","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib435","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3390\/biom15050636","article-title":"Microbial composition, disease trajectory and genetic background in a slow onset model of frontotemporal lobar degeneration","volume":"15","author":"Daude","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.pharmr.2026.100147_bib436","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.taap.2017.09.014","article-title":"DMARD use is associated with a higher risk of dementia in patients with rheumatoid arthritis: a propensity score-matched case-control study","volume":"334","author":"Chou","year":"2017","journal-title":"Toxicol Appl Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib437","first-page":"612","article-title":"Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients","volume":"3","author":"Judge","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib438","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13195-020-00606-5","article-title":"Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study","volume":"12","author":"Newby","year":"2020","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib439","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229819","article-title":"Tumor necrosis factor (TNF) blocking agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid arthritis and psoriasis","volume":"15","author":"Zhou","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib440","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3899\/jrheum.220200","article-title":"Risk factors for dementia in patients with incident rheumatoid arthritis: a population-based cohort study","volume":"50","author":"Kodishala","year":"2023","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib441","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-004016","article-title":"Association between disease-modifying antirheumatic drugs for rheumatoid arthritis and risk of incident dementia: a systematic review with meta-analysis","volume":"10","author":"Xie","year":"2024","journal-title":"RMD Open"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100147_bib442","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/s43587-022-00293-x","article-title":"Immune system-wide Mendelian randomization and triangulation analyses support autoimmunity as a modifiable component in dementia-causing diseases","volume":"2","author":"Lindbohm","year":"2022","journal-title":"Nat Aging"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib443","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40120-024-00609-6","article-title":"Methotrexate and the risk of dementia: a two-sample Mendelian randomization study","volume":"13","author":"Ma","year":"2024","journal-title":"Neurol Ther"},{"issue":"10423","key":"10.1016\/j.pharmr.2026.100147_bib444","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","article-title":"The pathogenesis of Parkinson's disease","volume":"403","author":"Morris","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib445","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson's disease and other synucleinopathies: From overt neurodegeneration back to early synaptic dysfunction","volume":"14","author":"Calabresi","year":"2023","journal-title":"Cell Death Dis"},{"issue":"23","key":"10.1016\/j.pharmr.2026.100147_bib446","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314753","article-title":"Pathogenesis of \u03b1-synuclein in Parkinson's disease: from a neuron-glia crosstalk perspective","volume":"23","author":"Yi","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib447","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/CM9.0000000000003989","article-title":"Role of LRRK2 in physiological activities, diseases, and therapy","volume":"139","author":"Wang","year":"2026","journal-title":"Chin Med J"},{"issue":"10291","key":"10.1016\/j.pharmr.2026.100147_bib448","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson's disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"issue":"2-3","key":"10.1016\/j.pharmr.2026.100147_bib449","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1385\/JMN:26:2-3:209","article-title":"Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function","volume":"26","author":"Fuxe","year":"2005","journal-title":"J Mol Neurosci"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib450","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.pharmthera.2011.07.004","article-title":"Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease","volume":"132","author":"Armentero","year":"2011","journal-title":"Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.pharmr.2026.100147_bib451","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.parkreldis.2020.09.025","article-title":"How do adenosine A(2A) receptors regulate motor function?","volume":"80","author":"Mori","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmr.2026.100147_bib452","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.REV120.014294","article-title":"Targeting mitophagy in Parkinson's disease","volume":"296","author":"Clark","year":"2021","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib453","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1096\/fj.201903051R","article-title":"AMPK activation induces mitophagy and promotes mitochondrial fission while activating TBK1 in a PINK1-Parkin independent manner","volume":"34","author":"Seabright","year":"2020","journal-title":"FASEB J"},{"issue":"35","key":"10.1016\/j.pharmr.2026.100147_bib454","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.2174\/138161282035140911142118","article-title":"Mitochondrial biogenesis: pharmacological approaches","volume":"20","author":"Valero","year":"2014","journal-title":"Curr Pharm Des"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib455","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3390\/antiox15020187","article-title":"Sources of oxidative stress in Parkinson's disease: pathways and therapeutic implications","volume":"15","author":"Yordanov","year":"2026","journal-title":"Antioxidants"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib456","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-025-02179-x","article-title":"Protein kinases in neurodegenerative diseases: current understandings and implications for drug discovery","volume":"10","author":"Wu","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100147_bib457","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.molmed.2024.07.003","article-title":"LRRK2 in Parkinson's disease: upstream regulation and therapeutic targeting","volume":"30","author":"Xiong","year":"2024","journal-title":"Trends Mol Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib458","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s12017-024-08812-2","article-title":"STAT3 inhibitor increases \u03b1-synuclein in PFF-treated astroglia cells by dysregulating autophagy and potentially affects exosome biogenesis","volume":"26","author":"Luo","year":"2024","journal-title":"Neuromolecular Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib459","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.948","article-title":"High expression of the HMGB1-TLR4 axis and its downstream signaling factors in patients with Parkinson's disease and the relationship of pathological staging","volume":"8","author":"Yang","year":"2018","journal-title":"Brain Behav"},{"key":"10.1016\/j.pharmr.2026.100147_bib460","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fnmol.2017.00013","article-title":"HMGB1 mediates autophagy dysfunction via perturbing Beclin1-Vps34 complex in dopaminergic cell model","volume":"10","author":"Huang","year":"2017","journal-title":"Front Mol Neurosci"},{"issue":"Pt 1","key":"10.1016\/j.pharmr.2026.100147_bib461","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.expneurol.2015.11.003","article-title":"Anti-high mobility group box 1 antibody exerts neuroprotection in a rat model of Parkinson's disease","volume":"275","author":"Sasaki","year":"2016","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmr.2026.100147_bib462","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.615075","article-title":"Review: the role of intestinal dysbiosis in Parkinson's disease","volume":"11","author":"Huang","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100147_bib463","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00702-002-0808-2","article-title":"Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen","volume":"110","author":"Braak","year":"2003","journal-title":"J Neural Transm"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100147_bib464","doi-asserted-by":"crossref","first-page":"e1273","DOI":"10.1212\/WNL.0000000000013303","article-title":"Disease-modifying antirheumatic drugs and risk of Parkinson disease: nested case-control study of people with rheumatoid arthritis","volume":"98","author":"Paakinaho","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.pharmr.2026.100147_bib465","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.2147\/CLEP.S381289","article-title":"Identification of drugs associated with lower risk of Parkinson's disease using a systematic screening approach in a nationwide nested case-control study","volume":"14","author":"Koponen","year":"2022","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.pharmr.2026.100147_bib466","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114386","article-title":"Genetic evidence of methotrexate's protective role against Parkinson's disease: a Mendelian randomization and co-localization study","volume":"152","author":"Zou","year":"2025","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib467","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/pds.5407","article-title":"Core concepts in pharmacoepidemiology: confounding by indication and the role of active comparators","volume":"31","author":"Sendor","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib468","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087965","article-title":"Confounding by indication probably distorts the relationship between steroid use and cardiovascular disease in rheumatoid arthritis: results from a prospective cohort study","volume":"9","author":"van Sijl","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmr.2026.100147_bib469","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1254753","article-title":"Dyslipidemia in rheumatoid arthritis: the possible mechanisms","volume":"14","author":"Yan","year":"2023","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100147_bib470","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/acr.25537","article-title":"Metabolic consequences of rheumatoid arthritis","volume":"77","author":"Barry","year":"2025","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib471","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2016.03.004","article-title":"Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib472","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0002-9343(02)01021-5","article-title":"Homocysteine and cardiovascular disease: current evidence and future prospects","volume":"112","author":"Mangoni","year":"2002","journal-title":"Am J Med"},{"issue":"2 Pt 1","key":"10.1016\/j.pharmr.2026.100147_bib473","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.amjhyper.2004.08.036","article-title":"Short-term oral folic acid supplementation enhances endothelial function in patients with type 2 diabetes","volume":"18","author":"Mangoni","year":"2005","journal-title":"Am J Hypertens"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib474","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1046\/j.1532-5415.2001.49196.x","article-title":"Vascular and blood pressure effects of folic acid in older patients with cardiovascular disease","volume":"49","author":"Mangoni","year":"2001","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100147_bib475","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1046\/j.1365-2796.2002.01059.x","article-title":"Folic acid enhances endothelial function and reduces blood pressure in smokers: a randomized controlled trial","volume":"252","author":"Mangoni","year":"2002","journal-title":"J Intern Med"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100147_bib476","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jama.2015.2274","article-title":"Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial","volume":"313","author":"Huo","year":"2015","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib477","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.clnu.2024.05.034","article-title":"Folic acid supplementation for stroke prevention: a systematic review and meta-analysis of 21 randomized clinical trials worldwide","volume":"43","author":"Zhang","year":"2024","journal-title":"Clin Nutr"},{"key":"10.1016\/j.pharmr.2026.100147_bib478","doi-asserted-by":"crossref","DOI":"10.1177\/17539447231215213","article-title":"Methotrexate and cardiovascular prevention: an appraisal of the current evidence","volume":"17","author":"Mangoni","year":"2023","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100147_bib479","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41574-018-0048-7","article-title":"Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications","volume":"14","author":"Biessels","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.pharmr.2026.100147_bib480","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1087571","article-title":"A meta-analysis investigating the relationship between inflammation in autoimmune disease, elevated CRP, and the risk of dementia","volume":"14","author":"Cooper","year":"2023","journal-title":"Front Immunol"},{"issue":"22","key":"10.1016\/j.pharmr.2026.100147_bib481","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.032506","article-title":"Intracranial atherosclerosis disease associated with cognitive impairment and dementia: systematic review and meta-analysis","volume":"12","author":"Sabayan","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib482","doi-asserted-by":"crossref","DOI":"10.1002\/cbf.4111","article-title":"Association between type 2 diabetes mellitus and Alzheimer's disease: common molecular mechanism and therapeutic targets","volume":"42","author":"Chauhan","year":"2024","journal-title":"Cell Biochem Funct"},{"key":"10.1016\/j.pharmr.2026.100147_bib483","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2025.115460","article-title":"Update on autoimmune dementia and its precursors","volume":"482","author":"Hansen","year":"2025","journal-title":"Behav Brain Res"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib484","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF01059737","article-title":"Pharmacokinetics of methotrexate in solid tumors","volume":"7","author":"Jain","year":"1979","journal-title":"J Pharmacokinet Biopharm"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib485","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1124\/dmd.112.049254","article-title":"Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate","volume":"41","author":"Li","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100147_bib486","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/s41423-021-00757-x","article-title":"The blood-brain barrier in systemic infection and inflammation","volume":"18","author":"Galea","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100147_bib487","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/pharmaceutics17020269","article-title":"Development and transportation pathway evaluation of liposomes with bile acids for enhancing the blood-brain barrier penetration of methotrexate","volume":"17","author":"Charernsriwilaiwat","year":"2025","journal-title":"Pharmaceutics"},{"issue":"39","key":"10.1016\/j.pharmr.2026.100147_bib488","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.2174\/1381612825666191112091700","article-title":"Methotrexate and vasculoprotection: mechanistic insights and potential therapeutic applications in old age","volume":"25","author":"Mangoni","year":"2019","journal-title":"Curr Pharm Des"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100147_bib489","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1016\/S2666-7568(24)00007-2","article-title":"Prevalence of multimorbidity and polypharmacy among adults and older adults: a systematic review","volume":"5","author":"Nicholson","year":"2024","journal-title":"Lancet Healthy Longev"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100147_bib490","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/agm2.12045","article-title":"Factors associated with medication adherence in older patients: a systematic review","volume":"1","author":"Smaje","year":"2018","journal-title":"Aging Med"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100147_bib491","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/ijd.17758","article-title":"Comprehensive literature review evaluating the use, safety, and efficacy of subcutaneous methotrexate in the treatment of adult patients with moderate-to-severe plaque-type psoriasis","volume":"64","author":"Viguier","year":"2025","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100147_bib492","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/rheumatology\/keh512","article-title":"The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions","volume":"44","author":"Kinder","year":"2005","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib493","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/ard.2008.093690","article-title":"Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"15","key":"10.1016\/j.pharmr.2026.100147_bib494","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1161\/CIRCULATIONAHA.118.036846","article-title":"Trust the blinded randomized evidence that statin therapy rarely causes symptomatic side effects","volume":"138","author":"Peto","year":"2018","journal-title":"Circulation"},{"issue":"34","key":"10.1016\/j.pharmr.2026.100147_bib495","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Bytyci","year":"2022","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100147_bib496","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann Intern Med"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699726000359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699726000359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:26:36Z","timestamp":1790245596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699726000359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":496,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0031699726000359"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100147","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in methotrexate pharmacology and potential therapeutic uses in age-related cardiometabolic and neurodegenerative diseases","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100147"}}